GT Biopharma, Inc.
GTBP
$3.05
$0.113.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.67M | -13.16M | -12.35M | -11.35M | -9.64M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -112.00K | -543.00K | -159.00K | 18.00K | -995.00K |
| Change in Net Operating Assets | 841.00K | 801.00K | 25.00K | -374.00K | 522.00K |
| Cash from Operations | -10.94M | -12.90M | -12.48M | -11.71M | -10.11M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 7.86M | 12.89M | 13.37M | 15.22M | 10.01M |
| Cash from Investing | 7.86M | 12.89M | 13.37M | 15.22M | 10.01M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3.59M | 2.98M | 2.98M | 2.98M | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 3.59M | 2.98M | 2.98M | 2.98M | 0.00 |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 508.00K | 2.97M | 3.86M | 6.48M | -95.00K |